Evidence map›Paper›PMID 36539705›Full record

ArticleThe journal of headache and pain2022

Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study.

Holly M Crowe, Amelia K Wesselink, Lauren A Wise, Susan S Jick, Kenneth J Rothman, Ellen M Mikkelsen, Henrik T Sørensen, Elizabeth E Hatch

Open access · goldAbstract read
In one paragraph

Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Holly M CroweHarvard T.H. Chan School of Public Health, Department of Epidemiology, 677 Huntington Avenue, Boston, MA, 02115, USA. hcrowe@hsph.harvard.edu.
Amelia K WesselinkBoston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, MA, 02118, USA.
Lauren A WiseBoston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, MA, 02118, USA.
Susan S JickBoston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, MA, 02118, USA.
Kenneth J RothmanBoston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, MA, 02118, USA.
Ellen M MikkelsenAarhus University, Department of Clinical Epidemiology, Olof Palmes Allé 43-45, DK-8200, Aarhus N, Denmark.
Henrik T SørensenAarhus University, Department of Clinical Epidemiology, Olof Palmes Allé 43-45, DK-8200, Aarhus N, Denmark.
Elizabeth E HatchBoston University School of Public Health, Department of Epidemiology, 715 Albany Street, Boston, MA, 02118, USA.
Boston University · USAarhus University · DKHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMigraine is common among females of reproductive age (estimated prevalence:17-24%) and may be associated with reproductive health through underlying central nervous system excitability, autoimmune conditions, and autonomic dysfunction. We evaluated the extent to which pre-pregnancy migraine diagnosis and medication use are associated with risk of spontaneous abortion (SAB).

methodsWe analyzed data from a preconception study of pregnancy planners (2013-2021). Eligible participants self-identified as female, were aged 21-45 years, resided in the USA or Canada, and conceived during follow-up (n = 7890). Participants completed baseline and bimonthly follow-up questionnaires for up to 12 months or until a reported pregnancy, whichever occurred first. Pregnant participants then completed questionnaires during early (~ 8-9 weeks) and late (~ 32 weeks) gestation. We defined migraineurs as participants who reported a migraine diagnosis or use of a medication to treat migraine. Preconception questionnaires elicited migraine medication use during the past 4 weeks, and SAB on follow-up and pregnancy questionnaires. We used Cox regression models with gestational weeks as the time scale to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations among preconception migraine, migraine medication use, and SAB, controlling for potential demographic, medical, and lifestyle confounders.

resultsNineteen percent of study pregnancies ended in SAB. History of migraine before conception was not appreciably associated with SAB risk (HR = 1.03, 95% CI: 0.91-1.06). Use of any migraine medication was associated with a modest increase in SAB risk overall (HR = 1.14, 95% CI: 0.96-1.36). We observed the greatest increase in risk among those taking migraine medications daily (HR = 1.38, 95% CI: 0.81-2.35) and those taking prescription migraine prophylaxis (HR = 1.43, 95% CI: 0.72-2.84) or combination analgesic and caffeine medications (HR = 1.42, 95% CI: 0.99-2.04).

conclusionsMigraine medication use patterns suggesting greater underlying migraine severity were associated with increased risk of SAB. This research adds to the limited information available on the reproductive effects of migraine.

Indexed as

Abortion, SpontaneousMigraine DisordersCaffeineFemaleHumansPregnancyProportional Hazards ModelsProspective StudiesCaffeineEpidemiologyMigraineMiscarriagePregnancySpontaneous abortionTriptans

Identifiers

PMID36539705
PMCPMC9764528
OpenAlexW4312115186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.